Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Q1 2025 Earnings Call Transcript May 6, 2025 Dynavax Technologies Corporation misses on earnings expectations. Reported EPS is $0.01 EPS, expectations were $0.03. Operator: Good day ladies and ...

Richard Lepke; Senior Director, Investor Relations; Vir Biotechnology Inc. Marianne De Backer; Chief Executive Officer, Director; Vir Biotechnology Inc. Mark Eisner; ...

Interim results from the phase 2b B-Clear showed that bepirovirsen reduced levels of hepatitis B surface antigen (HBsAg ... are available – such as Gilead's polymerase inhibitor Viread ...

Hepatitis B affects almost 300 million people worldwide, according to GSK, and while nucleoside/nucleotide analogue (NA) drugs to treat it are available – such as Gilead’s polymerase inhibitor ...

Venture firms complement South Korea's chaebol industrial structure, not only in new ... a Saccharomyces cerevisiae-derived recombinant hepatitis B surface antigen vaccine. In November 1992 ...

Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients.

Spontaneous loss of hepatitis B e antigen (HBeAg) followed by seroconversion to anti-HBe usually coincides with normalization of serum alanine aminotransferase (ALT) levels, reduction in HBV DNA ...

Discover an awarding winning abstract from EASL 2025 that has called for more person-centred hepatitis screening. Learn more.

The company’s market share in the U.S. Hepatitis B adult vaccine market rose to 43%, reflecting its competitive positioning. However, increased spending on R&D and SG&A expenses indicated a ...

The unusual molecular makeup of Borrelia burgdorferi, which causes Lyme disease, may hold clues for understanding and treating the tick-borne disease.